©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113816
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113816
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113816
Table 2 The quality assessment according to Newcastle-Ottawa Scale of each retrospective study
| Ref. | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow-up long enough | Adequacy of follow up of cohorts | Total score |
| Lee et al[15], 2024 | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
| Adhoute et al[16], 2022 | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Casadei-Gardini et al[19], 2021 | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 8 | |
| Iavarone et al[18], 2021 | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | 8 | |
| Kuo et al[17], 2021 | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Choi et al[21], 2020 | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Lee et al[20], 2020 | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | 8 |
- Citation: Cheng Z, Yue AM. Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastrointest Oncol 2026; 18(1): 113816
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113816.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113816